Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2016 by Riccardo Braglia, 3B Future Health Fund I & II is based in Luxembourg and specializes in venture capital investments in early-stage healthcare companies. The fund has invested in over 20 startups and achieved its first exit in 2019 with the acquisition of AMAL Therapeutics.
This fund targets early-stage healthcare companies primarily in North America, Europe, and Israel, focusing on oncology and rare diseases. Investments typically range from $1 million to $12 million, with a preference for Series A rounds but openness to earlier stages. 3B Future Health Fund aims to build a diversified portfolio of 10-15 companies while reserving capital for follow-on investments.
Notable companies in the portfolio include NeoPhore, which collaborates with The Institute of Cancer Research; Geneos Therapeutics, which raised $5 million in Series A3 financing; and iOnctura, awarded EUR 17.5 million for pancreatic cancer therapy development. Other investments include AnaCardio, Domain Therapeutics, and Sibylla Biotech.
Submit your pitch through their form at 3bfuturehealth.com.
Yes, 3B Future Health Fund often leads investment rounds, particularly in Series A financing.
The fund reserves capital for follow-on investments to support portfolio companies as they grow.
The fund size is not explicitly stated, but it invests up to $12 million in each company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.